Omron 2002 Annual Report Download - page 15

Download and view the complete annual report

Please find page 15 of the 2002 Omron annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 52

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52

HCB
Omron Corporation 13
Employing a new
nebulizing method,
the portable,
battery-operated Mesh
Nebulizer NE-U22 is the
smallest and lightest in
the world.
Digital blood pressure
monitor HEM-637 is the
first wrist-type automatic
blood pressure monitor
in Japan that allows
users to view readings
obtained over a week in
graph form.
Digital thermometer
Ken-on-kun MC-610 is
the first thermometer in
Japan able to measure
body temperature from
the underarm in an
average of five seconds.
Healthcare Company (HCB) sales
increased 3.3 percent year-on-year to
¥40.6 billion, as firm demand overseas
offset soft consumer spending in
Japan.
In the domestic market, market
conditions continued to be challenging
due to changes in consumption
patterns and the distribution industry.
Omron launched several new products,
including the first thermometer in
Japan that measures body temperature
from the underarm in five seconds, a
nebulizer that uses innovative
technology, and a weight scale with a
body fat measurement monitor. Sales
were negatively impacted, however, by
weak consumer spending and
deflationary conditions. In the
healthcare services sector, Omron
worked to build a new business model
centered on the Kenko Tatsujin (Health
Master) series.
Outside Japan, steady consumption
in North America underpinned results,
as did successful sales policies tailored
to large customers. Results were also
firm in Europe, due to efforts to
minimize the effects of a short-term
Healthcare Company
0
10
20
30
40
50
2001 2002
(Billions of Yen)
drop in prices and cooperation with a
major distributor in Germany.
Conditions were difficult in Asia as the
downturn in the information
technology industry adversely
impacted consumer spending. Results
were solid in China, as consumption
increased strongly and the current
stage of inventory adjustments at
distributors was completed.
HCB is raising cost competitiveness
on a global basis and applying its
development strengths in overseas
markets. The Company’s new business
model that integrates hardware and
service operations is expected to
support strong gains in sales.
Net Sales